statistiche ricercatore

Continente	#
NA - Nord America	1.503
EU - Europa	599
AS - Asia	412
SA - Sud America	65
AF - Africa	13
Continente sconosciuto - Info sul continente non disponibili	2
Totale	2.594

Nazione	#
US - Stati Uniti d'America	1.495
GB - Regno Unito	228
SG - Singapore	149
CN - Cina	123
IT - Italia	108
SE - Svezia	57
DE - Germania	55
BR - Brasile	50
HK - Hong Kong	42
FI - Finlandia	33
RU - Federazione Russa	26
UA - Ucraina	25
VN - Vietnam	25
FR - Francia	22
TR - Turchia	19
IN - India	13
KR - Corea	13
BE - Belgio	10
ID - Indonesia	9
BG - Bulgaria	8
BD - Bangladesh	7
SI - Slovenia	7
AR - Argentina	5
CZ - Repubblica Ceca	5
ZA - Sudafrica	5
CA - Canada	4
CL - Cile	3
ES - Italia	3
MX - Messico	3
PK - Pakistan	3
PL - Polonia	3
EC - Ecuador	2
IQ - Iraq	2
JP - Giappone	2
KE - Kenya	2
MY - Malesia	2
PE - Perù	2
TN - Tunisia	2
AT - Austria	1
BO - Bolivia	1
CD - Congo	1
CO - Colombia	1
DK - Danimarca	1
EU - Europa	1
GE - Georgia	1
GH - Ghana	1
GR - Grecia	1
IE - Irlanda	1
IS - Islanda	1
JM - Giamaica	1
KZ - Kazakistan	1
MA - Marocco	1
MD - Moldavia	1
NL - Olanda	1
RO - Romania	1
SK - Slovacchia (Repubblica Slovacca)	1
SN - Senegal	1
TH - Thailandia	1
VE - Venezuela	1
XK - ???statistics.table.value.countryCode.XK???	1
Totale	2.594

Nome	#
Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms	500
NF-YA splice variants have different roles on muscle differentiation	359
Unravelling the Complexity of Inherited Retinal Dystrophies Molecular Testing: Added Value of Targeted Next-Generation Sequencing	338
Transplantation of genetically corrected human iPSC-derived progenitors in mice with limb-girdle muscular dystrophy	317
Amplicon-based next-generation sequencing: an effective approach for the molecular diagnosis of epidermolysis bullosa	304
Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group	301
Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study	279
AMPLICON-BASED NGS: AN EFFECTIVE APPROACH FOR THE MOLECULAR DIAGNOSIS OF EPIDERMOLYSIS BULLOSA	214
Totale	2.612

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	229	0	0	0	0	0	26	21	49	15	77	20	21
2021/2022	191	6	16	28	13	10	13	12	11	19	13	30	20
2022/2023	213	31	27	18	18	21	30	7	21	24	0	6	10
2023/2024	147	7	4	9	8	25	26	16	16	0	5	9	22
2024/2025	394	14	4	16	25	66	57	28	30	36	20	43	55
2025/2026	479	60	46	67	81	182	43	0	0	0	0	0	0
Totale													2.612